Drugs that are effective in the treatment of T2D, including those which decrease insulin resistance and restore insulin-signaling pathways, by diminishing competitive inhibition on the insulin-degrading enzyme (IDE), can be used in AD (intranasal insulin, glucagon-like peptide-1 receptor agonists, peroxisome proliferator-activated receptor-gamma agonists, and others still under study) [15]. This evidence concerns the gene IDE and Insulin resistance.